Tag:
Colcrys
Latest Headlines
Latest Headlines
Takeda snaps up URL Pharma in $800M+ deal
The Japanese company is buying the Philadelphia-based pharma for $800 million upfront, plus potential follow-up payments.
Nuedexta next in line for congressional questions
U.S. lawmakers haven't limited their latest pricing crusade to URL Pharma's Colcrys. As the Wall Street Journal Health Blog reports, the same group of congressional members who wrote URL to question
FDA bans unapproved gout treatments
FDA announced plans to ban unapproved gout treatments, favoring Mutual Pharmaceuticals' new version of the decades-old product, Colcrys. Hikma Pharma, which markets old-time colchicine, says its
URL Pharma critics decry 'shake-down letters'
Call it an object lesson in the pitfalls of reacting to online chatter about drugs. The drug in question: Colcrys, a new FDA-approved version of the common-and-very-old gout treatment colchicine,
